contract manufacturing

Pharmaceutical CDMO formulations market projects 10.6% CAGR through 2030, driven by peptide outsourcing and biologic innovations reshaping competitive dynamics.

AAV vector manufacturing market to surge from $874M (2025) to $5.2B (2034) as gene therapy breakthroughs drive demand for specialized production infrastructure.

Medical device CDMO market projected to reach $354B by 2033, expanding at 13.12% CAGR driven by increased outsourcing, connected devices, and home care demand.

FIH Mobile returned to profitability with $52.73M net profit in 2025, but surging memory chip prices pose significant margin risks ahead.

Lifecore Biomedical announces third commercial CDMO site transfer since October 2025, targeting 12% revenue CAGR through 2029.

UFPT executives to participate in KeyBanc Capital Markets virtual healthcare forum on March 18, with scheduled investor meetings.

Barfresh secured $7.3M in convertible financing and $2.4M government grant to expand Ohio facility, targeting $200M+ annual capacity by fiscal 2026.

$FMFC invests $2.5M for 15% stake in Philippines manufacturer, gaining 477K sq ft capacity and 3,500 employees—first major expansion outside Cambodia.

Charles River Labs divests CDMO and discovery units to GI Partners and IQVIA, reducing revenue but boosting profitability and raising 2026 earnings guidance.

Biopharmaceutical CMO market to grow from $21.16B in 2025 to $76.2B by 2035, driven by outsourcing demand and capacity constraints.